Insights on Clinical Trials

1. What Global Survey Says About Scant Patient Access To CAR-T Therapy 6/17/2025

   The Worldwide Network for Blood and Marrow Transplantation initiated a survey to understand cost, infrastructure, and regulatory differences affecting access.

2. Precision Project Management In Action 6/12/2025

   Discover how a tailored, risk-based project management approach was used to overcome the challenges of a complex Phase I/IIa FIH multi-country study of an advanced therapy medicinal product (ATMP).

3. Huntington's Disease Clinical Trials: Innovation, Challenges, And The Road Ahead 6/11/2025

   The Huntington’s disease (HD) landscape is undergoing rapid transformation driven by breakthroughs in gene-targeted therapies, small-molecule modulators, regenerative medicine, and digital innovation.

4. Leveraging AI To Transform Neurodegenerative Drug Development 6/11/2025

   Explore how AI is redefining the development pipeline for neurodegenerative diseases (NDDs), offering a path forward in the quest for effective, disease-modifying treatments.

5. How Strategic Resourcing Accelerates Biotech's Path From Preclinical To FIH 6/11/2025

   Explore how strategic resourcing, particularly through FSP models, empowers biotech sponsors to overcome common hurdles transitioning when from preclinical research to first-in-human (FIH) trials.

6. ThinkLive Cell and Gene Therapy Summit 2025 Summary 6/11/2025

   From patient support to intricate logistics, ThinkLive CGT Summit 2025 leaders tackled the essential commercial strategies needed to deliver these innovative therapies to patients globally.

7. Effective Recruitment Capabilities And Outstanding Customer Service 6/10/2025

   Hear from many customers who commend OpenClinica's effective recruitment capabilities, outstanding customer service, and adept problem resolution.

8. Optimizing Clinical Data: Reducing Redundancy For Efficiency 6/6/2025

   Enabling sites to focus solely on critical data facilitates faster data entry, reduces queries, and fosters better relationships between sponsors, CROs, and sites.

9. The Hidden Risk In Cell & Gene Therapy Commercialization 6/5/2025

   Of the root causes of new product launch failure, insufficient relative advantage is by far the most important. Let's take a closer look at lessons we can learn from two key (approved) cell therapies.

10. Everything To Know About Long-Term Data Collection For Cell And Gene Therapy Trials In The EU 6/4/2025

    Discover how to secure uninterrupted access to long-term trial data for CAR-T therapies by participating in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T Data Collection Initiative.